Gain Therapeutics, Inc. (GANX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Gain Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Gain Therapeutics, Inc. (GANX) has returned -39.75% so far this year and 1.57% over the past 12 months.

Based on dividend-adjusted daily data since Mar 18, 2021, GANX's average daily return is +0.01%, while the average monthly return is -0.26%.

Historically, 41% of months were positive and 59% were negative. The best month was Nov 2025 with a return of +78.6%, while the worst month was Jun 2024 at -49.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, GANX closed higher 45% of trading days. The best single day was Feb 24, 2026 with a return of +31.1%, while the worst single day was Dec 18, 2025 at -44.4%.

Gain Therapeutics, Inc. has an annualized alpha of -9.75%, beta of 1.11, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since March 19, 2021.

• This stock participated in 78.51% of S&P 500 Index downside but only -55.18% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GANX ranks 45 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Gain Therapeutics, Inc. (GANX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Gain Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Gain Therapeutics, Inc. was 94.08%, occurring on Aug 13, 2024. The portfolio has not yet recovered.

The current Gain Therapeutics, Inc. drawdown is 87.72%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Gain Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Gain Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.